STOCK TITAN

[SCHEDULE 13G] enVVeno Medical Corporation SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Kingdon group disclosed a passive holding in enVVeno Medical Corporation (NVNO). The filing reports that Kingdon Capital Management, L.L.C. and affiliated entities and individual Mark Kingdon together hold shared voting and dispositive power over 1,359,261 shares, representing 7.1% of the outstanding common stock. M. Kingdon Offshore Master Fund, L.P. and Kingdon GP, LLC each report 1,265,845 shares (6.6%). The filing states the securities are owned by advisory clients and were not acquired to change or influence control of the issuer. Signatures from authorized representatives and exhibits (Joint Filing Agreement and Control Person Identification) are attached.

Kingdon Group ha comunicato una partecipazione passiva in enVVeno Medical Corporation (NVNO). La dichiarazione indica che Kingdon Capital Management, L.L.C., entità affiliate e il singolo Mark Kingdon detengono congiuntamente il potere di voto e di disposizione su 1.359.261 azioni, pari al 7,1% del capitale sociale in circolazione. M. Kingdon Offshore Master Fund, L.P. e Kingdon GP, LLC segnalano ciascuno 1.265.845 azioni (6,6%). Il filing specifica che i titoli sono di proprietà di clienti consulenziali e non sono stati acquistati con l'intento di modificare o influenzare il controllo dell'emittente. Sono allegate le firme dei rappresentanti autorizzati e gli allegati (Accordo di Deposito Congiunto e Identificazione della Persona di Controllo).

Kingdon Group divulgó una tenencia pasiva en enVVeno Medical Corporation (NVNO). El informe señala que Kingdon Capital Management, L.L.C., entidades afiliadas y el individuo Mark Kingdon comparten el poder de voto y disposición sobre 1.359.261 acciones, que representan el 7,1% del capital social en circulación. M. Kingdon Offshore Master Fund, L.P. y Kingdon GP, LLC informan cada uno 1.265.845 acciones (6,6%). El documento indica que los valores pertenecen a clientes asesorados y no se adquirieron con el propósito de cambiar o influir en el control del emisor. Se anexan las firmas de los representantes autorizados y los anexos (Acuerdo de Presentación Conjunta e Identificación de la Persona de Control).

킹던 그룹은 enVVeno Medical Corporation(NVNO)에 대한 수동적 보유를 공시했습니다. 신고서에 따르면 Kingdon Capital Management, L.L.C.와 계열사들 및 개인 Mark Kingdon은 공동으로 1,359,261주에 대한 의결권 및 처분권을 보유하고 있으며, 이는 발행 보통주 중 7.1%에 해당합니다. M. Kingdon Offshore Master Fund, L.P.와 Kingdon GP, LLC는 각각 1,265,845주(6.6%)를 보고했습니다. 해당 증권은 자문 고객 소유이며 발행인의 지배권 변경이나 영향력을 행사하기 위해 취득된 것이 아니라고 명시되어 있습니다. 권한 있는 대리인의 서명과 첨부 문서(공동 제출 계약 및 통제 인물 식별)가 첨부되어 있습니다.

Kingdon Group a déclaré une participation passive dans enVVeno Medical Corporation (NVNO). Le dépôt indique que Kingdon Capital Management, L.L.C., des entités affiliées et l'individu Mark Kingdon détiennent conjointement le pouvoir de vote et de disposition sur 1 359 261 actions, représentant 7,1% du capital social en circulation. M. Kingdon Offshore Master Fund, L.P. et Kingdon GP, LLC déclarent chacun 1 265 845 actions (6,6%). Le document précise que les titres appartiennent à des clients conseillés et n'ont pas été acquis afin de modifier ou d'influencer le contrôle de l'émetteur. Les signatures des représentants autorisés et les pièces jointes (Accord de dépôt conjoint et Identification de la personne de contrôle) sont annexées.

Kingdon Group meldete eine passive Beteiligung an der enVVeno Medical Corporation (NVNO). Die Meldung besagt, dass Kingdon Capital Management, L.L.C., verbundene Einheiten und die natürliche Person Mark Kingdon gemeinsam über Stimm- und Verfügungsmacht für 1.359.261 Aktien verfügen, was 7,1% des ausstehenden Stammkapitals entspricht. M. Kingdon Offshore Master Fund, L.P. und Kingdon GP, LLC geben jeweils 1.265.845 Aktien (6,6%) an. In der Einreichung steht, dass die Wertpapiere im Besitz von Beratungskunden sind und nicht erworben wurden, um die Kontrolle des Emittenten zu ändern oder zu beeinflussen. Unterschriften befugter Vertreter sowie Anlagen (Joint Filing Agreement und Identifikation der Kontrollperson) sind beigefügt.

Positive
  • Reported ownership above the 5% threshold: 1,359,261 shares (7.1%) provides clear regulatory disclosure
  • Detailed attribution: Separate reporting for Kingdon Capital Management, M. Kingdon Offshore Master Fund, Kingdon GP, LLC and Mark Kingdon aids transparency
  • Certification of passive intent: Statement that securities were not acquired to influence or change control is explicitly included
Negative
  • No sole voting or dispositive power: All reporting persons list zero sole voting and sole dispositive power
  • Majority of shares held via advisory clients: All securities are directly owned by advisory clients, limiting direct control (as stated)
  • Potential ambiguity on exact list of advisory clients: The filing notes clients hold the securities but does not identify them individually

Insights

TL;DR: Kingdon entities report a >5% passive stake (7.1%) in NVNO with shared voting/dispositive power; filing asserts non-control intent.

The Schedule 13G indicates a publicly reportable position: 1,359,261 shares (7.1%) reported by Kingdon Capital Management and Mark Kingdon, with M. Kingdon Offshore Master Fund and Kingdon GP reporting 1,265,845 shares (6.6%). All reported holdings show zero sole voting or dispositive power and instead list shared voting and dispositive power, consistent with advisory-client ownership. The statement explicitly certifies the holdings were not acquired to influence control, supporting a passive investor classification under Rule 13d-1(b).

TL;DR: Disclosure is material for governance monitoring—>5% ownership triggers reporting; structure shows advisory ownership and disclaimer of control.

The filing provides required transparency for a stakeholder above the 5% threshold. It identifies the reporting persons, their jurisdictions, exact share counts, percentages of class, and the lack of sole voting or dispositive authority. The inclusion of a joint filing agreement and a control-person identification exhibit aligns with standard governance disclosure practices. The signed certification reiterates the passive nature of the position.

Kingdon Group ha comunicato una partecipazione passiva in enVVeno Medical Corporation (NVNO). La dichiarazione indica che Kingdon Capital Management, L.L.C., entità affiliate e il singolo Mark Kingdon detengono congiuntamente il potere di voto e di disposizione su 1.359.261 azioni, pari al 7,1% del capitale sociale in circolazione. M. Kingdon Offshore Master Fund, L.P. e Kingdon GP, LLC segnalano ciascuno 1.265.845 azioni (6,6%). Il filing specifica che i titoli sono di proprietà di clienti consulenziali e non sono stati acquistati con l'intento di modificare o influenzare il controllo dell'emittente. Sono allegate le firme dei rappresentanti autorizzati e gli allegati (Accordo di Deposito Congiunto e Identificazione della Persona di Controllo).

Kingdon Group divulgó una tenencia pasiva en enVVeno Medical Corporation (NVNO). El informe señala que Kingdon Capital Management, L.L.C., entidades afiliadas y el individuo Mark Kingdon comparten el poder de voto y disposición sobre 1.359.261 acciones, que representan el 7,1% del capital social en circulación. M. Kingdon Offshore Master Fund, L.P. y Kingdon GP, LLC informan cada uno 1.265.845 acciones (6,6%). El documento indica que los valores pertenecen a clientes asesorados y no se adquirieron con el propósito de cambiar o influir en el control del emisor. Se anexan las firmas de los representantes autorizados y los anexos (Acuerdo de Presentación Conjunta e Identificación de la Persona de Control).

킹던 그룹은 enVVeno Medical Corporation(NVNO)에 대한 수동적 보유를 공시했습니다. 신고서에 따르면 Kingdon Capital Management, L.L.C.와 계열사들 및 개인 Mark Kingdon은 공동으로 1,359,261주에 대한 의결권 및 처분권을 보유하고 있으며, 이는 발행 보통주 중 7.1%에 해당합니다. M. Kingdon Offshore Master Fund, L.P.와 Kingdon GP, LLC는 각각 1,265,845주(6.6%)를 보고했습니다. 해당 증권은 자문 고객 소유이며 발행인의 지배권 변경이나 영향력을 행사하기 위해 취득된 것이 아니라고 명시되어 있습니다. 권한 있는 대리인의 서명과 첨부 문서(공동 제출 계약 및 통제 인물 식별)가 첨부되어 있습니다.

Kingdon Group a déclaré une participation passive dans enVVeno Medical Corporation (NVNO). Le dépôt indique que Kingdon Capital Management, L.L.C., des entités affiliées et l'individu Mark Kingdon détiennent conjointement le pouvoir de vote et de disposition sur 1 359 261 actions, représentant 7,1% du capital social en circulation. M. Kingdon Offshore Master Fund, L.P. et Kingdon GP, LLC déclarent chacun 1 265 845 actions (6,6%). Le document précise que les titres appartiennent à des clients conseillés et n'ont pas été acquis afin de modifier ou d'influencer le contrôle de l'émetteur. Les signatures des représentants autorisés et les pièces jointes (Accord de dépôt conjoint et Identification de la personne de contrôle) sont annexées.

Kingdon Group meldete eine passive Beteiligung an der enVVeno Medical Corporation (NVNO). Die Meldung besagt, dass Kingdon Capital Management, L.L.C., verbundene Einheiten und die natürliche Person Mark Kingdon gemeinsam über Stimm- und Verfügungsmacht für 1.359.261 Aktien verfügen, was 7,1% des ausstehenden Stammkapitals entspricht. M. Kingdon Offshore Master Fund, L.P. und Kingdon GP, LLC geben jeweils 1.265.845 Aktien (6,6%) an. In der Einreichung steht, dass die Wertpapiere im Besitz von Beratungskunden sind und nicht erworben wurden, um die Kontrolle des Emittenten zu ändern oder zu beeinflussen. Unterschriften befugter Vertreter sowie Anlagen (Joint Filing Agreement und Identifikation der Kontrollperson) sind beigefügt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Kingdon Capital Management, L.L.C.
Signature:/s/ Richard Weinstein
Name/Title:Richard Weinstein/Chief Operating Officer & General Counsel
Date:09/09/2025
M. Kingdon Offshore Master Fund, L.P.
Signature:By: Kingdon GP, LLC, its general partner, By: /s/ Mark Kingdon
Name/Title:Mark Kingdon/Managing Member
Date:09/09/2025
Kingdon GP, LLC
Signature:/s/ Mark Kingdon
Name/Title:Mark Kingdon/Managing Member
Date:09/09/2025
Mark Kingdon
Signature:/s/ Mark Kingdon
Name/Title:Mark Kingdon
Date:09/09/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

FAQ

What stake in NVNO does Kingdon Capital Management report?

Kingdon Capital Management, L.L.C. reports beneficial ownership of 1,359,261 shares, equal to 7.1% of the common stock.

How much does M. Kingdon Offshore Master Fund own in NVNO?

M. Kingdon Offshore Master Fund, L.P. reports ownership of 1,265,845 shares, representing 6.6% of the class.

Do the reporting persons have sole voting or dispositive power over the shares?

No. Each reporting person indicates 0 sole voting power and 0 sole dispositive power, and reports shared voting and dispositive power instead.

Was the position acquired to influence control of enVVeno Medical Corporation?

The filing includes a certification stating the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Are exhibits included with the Schedule 13G filing?

Yes. The filing lists Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification).
Envveno Medical Corporation

NASDAQ:NVNO

NVNO Rankings

NVNO Latest News

NVNO Latest SEC Filings

NVNO Stock Data

17.74M
17.78M
0.84%
29.88%
13.49%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE